首頁 關於我們 醫療團隊 趙效明 醫師

趙效明 醫師

學歷:

英國牛津大學    博士(D. Phil.)

                       

現任:

新光醫學中心眼科主治醫師

國立陽明大學醫學系暨藥理研究所 副教授

英國臺灣學術協會現任理事

英國牛津大學眼科醫學會員(Member, Oxford Ophthalmological Congress)

中國醫藥研發基金會董事

BMC Ophthalmology 期刊主編

奧比斯眼科飛航醫院  玻璃體網膜手術醫師

 

經歷:

振興醫院眼科部 部主任

台北榮總眼科部主治醫師

牛津眼科醫院臨床研究員

中國醫藥大學附設醫院眼科主治醫師

中華民國網膜醫學會首屆執行秘書長

 

主治項目:

飛秒雷射微創白內障超音波晶體乳化術

黃斑病變玻璃體抗體注射

糖尿病視網膜病變玻璃體抗體注射

視網膜剝離手術及鐳射治療

黃斑破洞、皺褶手術治療

青光眼雷射手術治療

正常眼壓青光眼

飛蚊症

乾眼症診斷治療

葡萄膜炎

一般眼科疾病診斷治療

 

學術研究

  • Osborne, N. N., Ugarte, M., Chao, H. M., Chidlow, G., Bae, J. H., Wood, J. P. and Nash, M. S. (1999) Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol, 43 (Suppl. 1): S102-S128
  • Osborne, N. N., Wood, J. P., Melena, J., Chao, H. M., Nash, M. S., Bron, A. J., and Chidlow, G. (2000) 5-Hydroxytryptamine1A agonists: potential use in glaucoma. Evidence from animal studies. Eye, 14(Pt 3b): 454-63
  • Chao, H. M., Chidlow, G., Melena, J., Wood, J. P. M. and Osborne, N. N. (2000) An investigation into the potential mechanisms underlying the neuroprotective effect of clonidine in the retina. Brain Res, 877(1): 47-57
  • Wood, J.P.M., DeSantis, L., Chao, H. M. and Osborne, N.N. (2001) Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp Eye Res, 72: 79-86
  • Chao, H. M. and Osborne, N. N. (2001) Topically applied clonidine protects the rat retina from ischaemia/reperfusion by stimulating 2-adrenoceptors and not by an action on imidazoline receptors. Brain Res, 904(1): 126-136
  • Chao, H. M. (2005) The Current Stem Cell Research. Clinical Medicine, 55: 326-332.
  • Chao, H. M., Chen S. J., Hsu W. M., Lee F. L., Chen, K. H. (2006) Siderosis Oculi. Cutaneous and Ocular Toxicology, 25(2): 131-140.
  • Chao HM, Lin DE, Chang Y, Hsu WM, Lee SM, Lee FL, Chi CW, Pan WH, Liu TY, Lui WY, Ho LT, Kuo CD, Chan CC, Chao FP (2008). Ferulic acid, but not tetramethylpyrazine, significantly attenuates retinal ischaemia/reperfusion-induced alterations by acting as a hydroxyl radical scavenger. Journal of Ocular Pharmacology and Therapeutic, 24(5):461-72.
  • Chao HM, Chen YH, Liu JH, Lee SM, Lee FL, Chang Y, Yeh PH, Pan WH, Chi CW, Liu TY, Lui WY, Ho LT, Kuo CD, Lin DE, Chan CC, Yang DM, Lin AM, Chao FP. (2008). Iron-generated Hydroxyl Radicals Kill Retinal Cells In Vivo: Effect of Ferulic Acid. Human Experimental Toxicology, 27(4):327-39.
  • Liu JH, Chen MM, Huang JW, Wann H, Ho LK, Pan WH, Chen YC, Liu CM, Yeh MY, Tsai SK, Young MS, Ho LT, Kuo CD, Chuang HY, Chao FP, Chao HM (2010).* Therapeutic effects and mechanisms of action of mannitol during H2O2-induced oxidative stress in human retinal pigment epithelium cells. J. Ocul. Pharmacol. Ther. 26(3):249-57. *, Correspondent Author.
  • Liu JH, Wann H, Chen MM, Pan WH, Chen YC, Liu CM, Yeh MY, Tsai SK, Young MS, Chuang HY, Chao FP, Chao HM (2010).* Baicalein significantly protects human retinal pigment epithelium cells against H2O2-induced oxidative stress by scavenging reactive oxygen species and downregulating the expression of matrix metalloproteinase-9 and vascular endothelial growth factor. J. Ocul. Pharmacol. Ther. 26(5):1-9. *, Correspondent Author.
  • Peng PH, Chiou LF, Chao HM, Lin S, Chen CF, Liu JH, Ko ML (2010). Effects of epigallocatechin-3-gallate on rat retinal ganglion cells after optic nerve axotomy. Exp Eye Res., 90(4):528-34.
  • Pai-Huei Peng, Hsiao-Ming Chao, Shu-Hui Juan, Chau-Fong Chen, Jorn-Hon Liu, Mei-Lan Ko (2011). Pharmacological Preconditioning by Low Dose Cobalt Protoprophyrin Induces Heme Oxygenase-1 Overexpression and Alleviates Retinal Ischemia-Reperfusion Injury in Rats. Curr. Eye Res., 36(3):238-46.
  • Chen YQ, Pan WH, Liu JH, Chen MM, Liu CM, Yeh MY, Tsai SK, Young MS, Zhang XM, Chao HM (2012).* The effects and underlying mechanisms of S-allyl L-cysteine treatment of the retina after ischemia/reperfusion. J. Ocul. Pharmacol. Ther., 28(2):110-7.
  • Chao HM, Chuang MJ, Liu JH, Liu XQ, Ho LK, Pan WH, Zhang XM, Liu CM, Tsai SK, Kong CW, Lee SD, Chen MM, Chao FP (2013). Baicalein protects against retinal ischemia by antioxidation, antiapoptosis, downregulation of HIF-1α, VEGF, and MMP-9 and upregulation of HO-1. J. Ocul. Pharmacol. Ther. Jul-Aug;29(6):539-49.
  • Liu XQ, Wu BJ, Pan WH, Zhang XM, Liu JH, Chen MM, Chao FP, Chao HM (2013).* Resveratrol mitigates rat retinal ischemic injury: roles of MMP-9, iNOS, and HO-1. J. Ocul. Pharmacol. Ther. 29(1):33-40. *: Correspondent Author.
  • Hsu TK, Liu JH, Lei J, Chao HM (2013).* Retinal angiomatous proliferation responds safely to a double dose (1.0 mg) of ranibizumab. Clin Exp Optom. 96(1):112-6. *: Correspondent Author.
  • Hsu TK, Chen SJ, Lei J, Wu Z, Lin CC, Chen MM, Lin TC, Liu JH, Chao HM (2013).* Embolus-induced branch retinal artery occlusion with presenting vision of < 0.5: YAG embolectomy safely restores arteriolar perfusion and/or visual function. Retin. Cases Brief Rep. 7(3):210-6. *, Correspondent Author.
  • Chao HM, Chen IL, Liu JH (2014). S-allyl L-cysteine protects the retina against kainate excitotoxicity in the rat. Am J Chin Med. 42(3):693-708. (Impact factor 3.510).
  • Hsiao-Ming Chao (2016),* L Hu, JM Cheng, XQ Liu, JH Liu, WHT Pan, XM Zhang.* Chi-Ju-Di-Huang-Wan protects against retinal ischemia by downregulating matrix metalloproteinase-9 via p38 mitogen-activated protein kinase inhibition in the rat. Chin Med. 11(1):39. *, Correspondent Author. (Impact factor 2.343).
  • SQ Tan, X Geng, JH Liu, WHT Pan, LX Wang, HK Liu, L Hu, HM Chao (2017).* Xue-Fu-Zhu-Yu Decoction protects rats against retinal ischemia by downregulation of HIF-1α and VEGF via inhibition of RBP2 and PKM2. BMC Complementary and Alternative Medicine. 2017 Jul 14;17(1):365. *, Correspondent Author. (Impact factor 2.195).
  • Wen-Haur Chao, Ming-Yi Lai, Hwai-Tzong Pan, Huei-Wen Shiu, Mi-Mi Chen, Hsiao-Ming Chao (2018).* Dendrobium nobile Lindley and its bibenzyl component moscatilin are able to protect retinal cells from ischemia/hypoxia by dowregulating placental growth factor and upregulating Norrie disease protein. BMC Complement Altern Med. 2018 Jun 22;18(1):193. *, Correspondent Author. (Impact factor 2.195).
  • Ding-Ying Liao, Jorn-Hon Liu, Yu-Ping Zheng, Jian-Ming Wang, Hsiao-Ming Chao (2020).* Posterior vitreous detachment by consecutive SD-OCT: prevalence; floaters; incidence of vision-threatening retinal complications and its relation to the vitreomacular angle. BMC Ophthalmol. 2020 Apr 22;20(1):163. *, Correspondent Author. (Impact factor 1.431).
  • Windsor Wen-Jin Chao, Shu-Qiu Tan, Jorn-Hon Liu, Mi-Mi Chen, Huei-Wen Shiu, Hsiao-Ming Chao (2020).* Dry eye: the effect of Chi‑Ju‑Di‑Huang‑Wan plus Si Wu Tang and the underlying mechanism. Journal of Alternative and Complementary Medicine. 2020 Feb;26(2):138-146.*, Correspondent Author. (Impact factor: 1.868; 12/27=44%).
  • Howard Wen-Haur Chao, Yu-Kuang Chen, Jorn-Hon Liu, Wynn Hwai-Tzong Pan, Hsin-Mei Lin, Hsiao-Ming Chao.* Emodin protected against retinal ischemia through downregulating the β-catenin protein overexpression (submitted to BMC Complement Altern Med for publication; Under review). *, Correspondent Author. (Impact factor 2.195).
  • Windsor Wen-Jin Chao, Yu-Kuang Chen, Howard Wen-Haur Chao, Wynn Hwai-Tzong Pan, Hsiao-Ming Chao.* Fortified S-allyl L-cysteine: animal safety; the effect on retinal ischemia and the role of Wnt in the underlying therapeutic mechanism. (submitted to Evidence based Complement Altern Med for publication; Major revision). *, Correspondent Author. (Impact factor 2.195).
  • Hsiao-Ming Chao* and Jorn-Hon Liu. Indocyanine green-assisted internal limiting membrane peeling in idiopathic macular pucker: prognostic factors (submitted to BMC Ophthalmol. for publication; Under review). *, Correspondent Author. (Impact factor 1.431).
  • Hsiao-Ming Chao* and Jorn-Hon Liu. One-year results of polypoidal choroidal vasculopathy with anti-vascular endothelium growth factor aflibercept or ranibizumab with/without verteporphin photodynamic therapy: systemic review (submitted to BMC Ophthalmol. for publication; Under review). *, Correspondent Author. (Impact factor 1.431).

109/07/01起,趙效明醫師双眼明眼科體系門診時間

  星期一 星期二 星期三 星期四 星期五 星期六
      大安